These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1970155)

  • 21. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
    Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
    Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered gene expression in drug-resistant human breast cancer cells.
    Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
    Albor A; Thraves PJ; Dritschilo A; Notario V
    Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
    Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ras and neu oncogenes reverse serum inhibition and epidermal growth factor dependence of serum-free mouse embryo cells.
    Shirahata S; Rawson C; Loo D; Chang YJ; Barnes D
    J Cell Physiol; 1990 Jul; 144(1):69-76. PubMed ID: 1973170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
    Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
    Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
    Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL
    Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes.
    Shibuya M; Matsushime H; Yamazaki H; Wang LH; Fukui Y; Ueyama Y; Tamaoki N
    Princess Takamatsu Symp; 1986; 17():195-202. PubMed ID: 3455414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP; Kokeny KE; Ridings JW; Dilts CA
    Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
    Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
    van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R
    Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell transformation by the epidermal growth factor receptor and v-erbB.
    Hayman MJ; Enrietto PJ
    Cancer Cells; 1991 Aug; 3(8):302-7. PubMed ID: 1681843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase.
    Sistonen L; Hölttä E; Lehväslaiho H; Lehtola L; Alitalo K
    J Cell Biol; 1989 Nov; 109(5):1911-9. PubMed ID: 2572601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products.
    Yan DH; Chang LS; Hung MC
    Oncogene; 1991 Feb; 6(2):343-5. PubMed ID: 1672040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.
    Tarakhovsky A; Zaichuk T; Prassolov V; Butenko ZA
    Oncogene; 1991 Dec; 6(12):2187-96. PubMed ID: 1685016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
    EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential expression of the dbl protooncogene in some tumors of neuroectodermal origin.
    de Franciscis V; Rosati R; Colucci-D'Amato GL; Eva A; Vecchio G
    Cancer Res; 1991 Aug; 51(16):4234-7. PubMed ID: 1868443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.